Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Mendelian Genomics, |
RCV000414759 | SCV000493044 | likely pathogenic | Progressive distal muscle weakness; Progressive proximal muscle weakness | 2014-03-19 | criteria provided, single submitter | clinical testing | |
Centre for Mendelian Genomics, |
RCV000626902 | SCV000747605 | pathogenic | Urinary bladder sphincter dysfunction; EMG: myopathic abnormalities; Distal amyotrophy; Foot dorsiflexor weakness; Distal lower limb muscle weakness; Lower limb pain; Fatty replacement of skeletal muscle; Muscle fiber inclusion bodies | 2017-01-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000794536 | SCV000933950 | pathogenic | Myofibrillar myopathy 3 | 2024-12-16 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with phenylalanine, which is neutral and non-polar, at codon 55 of the MYOT protein (p.Ser55Phe). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with myofibrillar myopathy, limb-girdle muscular dystrophy, and other forms of myotilinopathies (PMID: 9027924, 12428213, 15111675, 15947064, 16684602, 21676617, 25208129, 26342832). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 5835). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt MYOT protein function with a positive predictive value of 95%. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on MYOT function (PMID: 21361873). For these reasons, this variant has been classified as Pathogenic. |
Ce |
RCV001091589 | SCV001247721 | pathogenic | not provided | 2017-01-01 | criteria provided, single submitter | clinical testing | |
Institute of Medical Genetics and Applied Genomics, |
RCV001091589 | SCV001447480 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
MGZ Medical Genetics Center | RCV000794536 | SCV002580234 | likely pathogenic | Myofibrillar myopathy 3 | 2021-09-02 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000794536 | SCV000026373 | pathogenic | Myofibrillar myopathy 3 | 2004-04-27 | no assertion criteria provided | literature only |